ReviewDrugs in context2020

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure.

Edgardo KaplinskyPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.